ASH 2022 Highlights Podcast Presented ByRobert van den Heuvel, Medicom ConferenceASH 2022 5 January, 2023 02:23
Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial Presented ByDr Nizar Bahlis, University of Calgary, Canada TrialPhase 3, MagnetisMM-3 ConferenceASH 2022 14 December, 2022 10:53
Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma Presented ByProf. Martin Dreyling, University Hospital Munich, Germany TrialPhase 3, Triangle ConferenceASH 2022 13 December, 2022 11:33
Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL Presented ByDr Mark Litzow, Mayo Clinic, MN, USA TrialPhase 3, ECOG-ACRIN E1910 ConferenceASH 2022 15 December, 2022 11:26
Novel therapy may replace standard-of-care prophylaxis for GVHD Presented ByDr Shernan Holtan, University of Minnesota, MN, USA TrialPhase 3, BMT CTN 1703 ConferenceASH 2022 15 December, 2022 11:24
High-dose chemotherapy plus ASCT superior to standard immune-chemotherapy in primary CNS lymphoma Presented ByProf. Gerald Illerhaus, Klinikum Stuttgart, Germany TrialPhase 3, MATRix/IELSG43 ConferenceASH 2022 15 December, 2022 11:23
Odronextamab scores in relapsed/refractory diffuse large B-cell lymphoma Presented ByDr Won-Seog Kim, Samsung Medical Center, South Korea TrialPhase 2, ELM-2 ConferenceASH 2022 15 December, 2022 11:21
LMWH does not result in higher live birth rates in women with inherited thrombophilia Presented ByProf. Saskia Middeldorp, Radboud UMC, the Netherlands TrialALIFE2 ConferenceASH 2022 15 December, 2022 11:20
Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care Presented ByProf. Régis de Latour, Saint-Louis Hospital, Paris, France TrialPhase 3, Apply-PNH ConferenceASH 2022 15 December, 2022 11:19
Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial Presented ByDr Nizar Bahlis, University of Calgary, Canada TrialPhase 3, MagnetisMM-3 ConferenceASH 2022 14 December, 2022 10:53
Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML? TrialPhase 3, ASAP ConferenceASH 2022 14 December, 2022 10:52
Excellent results for triplet regimen in FLT3-mutated AML Presented ByDr Nicholas Short, University of Texas, TX, USA TrialPhase 1/2 ConferenceASH 2022 14 December, 2022 10:51
MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML Presented ByJad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK ConferenceASH 2022 14 December, 2022 10:50
CAR-hematotox score predicts toxicity, infections, and clinical outcomes in MCL Presented ByDr Kai Rejeski, LMU Munich, Germany ConferenceASH 2022 14 December, 2022 10:49
Deep and durable responses for quadruple therapy in smouldering MM Presented ByDr Shaji Kumar, Mayo Clinic, MN, USA TrialPhase 2, ASCENT ConferenceASH 2022 14 December, 2022 10:48
Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma Presented ByProf. Martin Dreyling, University Hospital Munich, Germany TrialPhase 3, Triangle ConferenceASH 2022 13 December, 2022 11:33
Efgartigimod successful in immune thrombocytopenia Presented ByDr Catherine Broome, Georgetown University, DC, USA TrialPhase 3, ADVANCE ConferenceASH 2022 13 December, 2022 11:32
Promising results for triplet therapy with magrolimab in AML Presented ByDr Naval Daver, Anderson Cancer Center, TX, USA ConferenceASH 2022 13 December, 2022 11:30
Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data Presented ByProf. Ajai Chari, Mount Sinai School of Medicine, NY, USA TrialPhase 1/2, MonumenTAL-1 ConferenceASH 2022 13 December, 2022 11:29
High-dose methotrexate or standard interim maintenance in young patients with ALL? Presented ByAmy Kirkwood, University College London, UK TrialPhase 3, UKALL 2011 ConferenceASH 2022 13 December, 2022 11:28
Ibrutinib plus venetoclax displays long-term benefits in CLL Presented ByDr John Allan, Weill Cornell Medicine, NY, USA ConferenceASH 2022 13 December, 2022 11:26